Revisiting the Association between Human Leukocyte Antigen and End-Stage Renal Disease

AbstractMultiple works have studied possible associations between human leukocyte antigen (HLA) alleles and end stage renal disease (ESRD) showing, however, contradictory and inconsistent results. Here, we revisit the association between ESRD and HLA antigens, comparing HLA polymorphism (at HLA-A, -B, -C, -DRB1, -DQB1 and DQA1 loci) in ESRD patients (n=497) and controls (n=672). Our data identified several HLA alleles that displayed a significant positive or negative association with ESRD. We also determined whether heterozygosity or homozygosity of the ESRD-associated HLA alleles at different loci could modify the prevalence of the disease. Few HLA allele combinations displayed significant associations with ESRD among which HLA-A*3–HLA-A*26 combination showed the highest strength of association (OR= 4.488, P≤ 0.05) with ESRD. Interestingly, the age of ESRD onset was not affected by HLA allele combinations at different loci. We also performed an extensive literature analysis to determine whether the association of HLA to ESRD can be similar across different ethnic groups. Our analysis showed at least for certain alleles, HLA-A*11, HLA-DRB1*11, and HLA-DRB1*4, a significant association of HLA to ESRD in different ethnic groups. The findings of our study will help in determining possible protective or susceptible roles of various HLA alleles in ESRD.

Download Full-text

Risk factors of sensitization to human leukocyte antigen in end-stage renal disease patients

Human Immunology ◽

10.1016/j.humimm.2014.02.024 ◽

2014 ◽

Vol 75 (6) ◽

pp. 531-535 ◽

Cited By ~ 11

Author(s):

Shih-Yuan Hung ◽

Tsun-Mei Lin ◽

Min-Yu Chang ◽

Hsi-Hao Wang ◽

Yi-Che Lee ◽

...

Keyword(s):

Risk Factors ◽

Renal Disease ◽

Human Leukocyte Antigen ◽

End Stage Renal Disease ◽

Human Leukocyte ◽

Leukocyte Antigen ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Human leukocyte antigen polymorphisms as susceptibility risk factors for end stage renal disease

Genetika ◽

10.2298/gensr1902607a ◽

2019 ◽

Vol 51 (2) ◽

pp. 607-617 ◽

Cited By ~ 2

Author(s):

Dusica Ademovic-Sazdanic ◽

Svetlana Vojvodic

Keyword(s):

Risk Factors ◽

Renal Disease ◽

Human Leukocyte Antigen ◽

End Stage Renal Disease ◽

Human Leukocyte ◽

Leukocyte Antigen ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Association of Human Leukocyte Antigen Haplotypes With End-Stage Renal Disease in Vietnamese Patients Prior to First Transplantation

Transplantation Proceedings ◽

10.1016/j.transproceed.2019.03.067 ◽

2019 ◽

Vol 51 (8) ◽

pp. 2549-2554 ◽

Cited By ~ 1

Author(s):

Ho Trung Hieu ◽

Nguyen Thu Ha ◽

Le Huu Song ◽

Tran Hong Nghi

Keyword(s):

Renal Disease ◽

Human Leukocyte Antigen ◽

End Stage Renal Disease ◽

Human Leukocyte ◽

Leukocyte Antigen ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Revisiting the association between human leukocyte antigen and end-stage renal disease

PLoS ONE ◽

10.1371/journal.pone.0238878 ◽

2020 ◽

Vol 15 (9) ◽

pp. e0238878

Author(s):

Naila Noureen ◽

Farhad Ali Shah ◽

Jan Lisec ◽

Hina Usman ◽

Mohammad Khalid ◽

...

Keyword(s):

Renal Disease ◽

Human Leukocyte Antigen ◽

End Stage Renal Disease ◽

Human Leukocyte ◽

Leukocyte Antigen ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Evaluation of Human Leukocyte Antigen Class I and Class II in End-Stage Renal Disease Occurrence in Indonesian Transplantation Patients

International Journal of Nephrology ◽

10.1155/2021/4219822 ◽

2021 ◽

Vol 2021 ◽

pp. 1-6

Author(s):

Hani Susianti ◽

Dwi Priyadi Djatmiko ◽

I Komang Adi Widana ◽

Deasy Ayuningtyas Tandio ◽

Catur Suci Sutrisnani ◽

...

Keyword(s):

Renal Disease ◽

Human Leukocyte Antigen ◽

End Stage Renal Disease ◽

Human Leukocyte ◽

Class I ◽

Leukocyte Antigen ◽

Hla Genes ◽

Stage Renal Disease ◽

End Stage ◽

Esrd Patients

Background. Genetic studies of end-stage renal disease (ESRD), including those of human leukocyte antigen (HLA) genes, have been reported in several populations but have not yet been evaluated in Indonesia. Some studies have reported that these genes had a substantial role in ESRD. This study aims to analyze the association between HLA genes and ESRD within the Indonesian community. Method. A retrospective study to investigate HLA class I and II alleles to find out the distribution of HLA-A, -B, -C, -DPB1, -DQB1, and -DRB1 in renal transplant recipients and to ascertain their role in susceptibility to ESRD was performed on totally 149 subjects, consisting of 69 ESRD patients and 80 healthy controls. HLA typing was determined using Luminex techniques. The allele and haplotype frequencies were compared between ESRD patients and controls. Result. High-frequency alleles were HLA-A ∗ 24 (43.6%), B ∗ 15 (38.2%), C ∗ 08 (30.8%), DRB1 ∗ 12 (47.3%), DQB1 ∗ 03 (50.6%), and DPB1 ∗ 13 (22.5%). HLA-A ∗ 24 p = 0.01 and HLA-B ∗ 35 p = 0.02 were associated with a protective effect, with OR 0.537 (95%CI 0.34–0.86) and 0.316 (95%CI 0.11–0.88), respectively. There were some two-locus haplotypes associated with susceptibility to ESRD, such as B ∗ 15-DRB1 ∗ 12, B ∗ 13-DRB1 ∗ 15, A ∗ 02-B ∗ 15, A ∗ 02-C ∗ 08, and B ∗ 13-DQB1 ∗ 05. HLA-A ∗ 02-B ∗ 15-DRB1 ∗ 12 and A ∗ 24-B ∗ 13-DRB1 ∗ 15 appear to be associated with susceptibility to ESRD. Conclusion. The allele groups of HLA-A ∗ 24 and HLA-B ∗ 35 are associated with protection from ESRD. Meanwhile, HLA-B ∗ 13-DRB1 ∗ 15 and A ∗ 24-B ∗ 13-DRB1 ∗ 15 are the most frequent HLAs associated with ESRD in two-locus and three-locus haplotype, respectively.

Download Full-text

Plasmapheresis Therapy in Kidney Transplant Rejection

Blood Purification ◽

10.1159/000493521 ◽

2018 ◽

Vol 47 (1-3) ◽

pp. 73-84 ◽

Cited By ~ 3

Author(s):

Pan Xie ◽

Min Tao ◽

Kanfu Peng ◽

Hongwen Zhao ◽

Keqin Zhang ◽

...

Keyword(s):

End Stage Renal Disease ◽

Multimodal Treatment ◽

Transplant Rejection ◽

Human Leukocyte ◽

Economic Costs ◽

Leukocyte Antigen ◽

Antibody Mediated Rejection ◽

Stage Renal Disease ◽

End Stage ◽

Optimal Treatment Strategy

Kidney transplantation (KT) is considered an optimal treatment strategy for end-stage renal disease. But human leukocyte antigen-sensitized, ABO-incompatible and antibody-mediated rejection might be the alarming hurdles in KT. Therapeutic plasma exchange is the mainstay of the antibody reduction therapy for reducing autoantibody more effectively. Even in the treatment for highly sensitized patients, it has played an indispensable role. However, clinicians should tailor therapies to individual patient’s needs and multimodal treatment will bring better outcomes. Early diagnosis and precise treatment would reduce morbidity, mortality, and economic costs.

Download Full-text

A path to renal transplantation in Nepal

Journal of Pathology of Nepal ◽

10.3126/jpn.v1i1.4453 ◽

1970 ◽

Vol 1 (1) ◽

pp. 52-55

Author(s):

J Enns ◽

G Aryal

Keyword(s):

Renal Transplantation ◽

Renal Replacement Therapy ◽

Human Leukocyte Antigen ◽

Replacement Therapy ◽

Human Leukocyte ◽

Cost Effective ◽

Leukocyte Antigen ◽

Post Transplant ◽

Stage Renal Disease ◽

End Stage

End Stage Renal Disease affects many people in the world. There are three methods of renal replacement therapy available to patients: Continuous ambulatory peritoneal dialysis, haemodialysis and transplantation. Transplantation is the most viable and cost effective form of renal replacement therapy that is available for these patients. There are 3 factors required to help ensure a successful renal transplantation program: A well legislated donor and recipient program, Human Leukocyte Antigen testing (pre and post transplant), as well as a post transplant follow up program. Keywords: Renal Transplant; South Asia; Nepal; Human Leukocyte Antigen DOI: 10.3126/jpn.v1i1.4453 Journal of Pathology of Nepal (2011) Vol.1, 52-55

Download Full-text

Prospective payment system and racial/ethnic disparities: a national retrospective observational study in anaemia complication among end-stage renal disease patients in the US

BMC Nephrology ◽

10.1186/s12882-020-02081-4 ◽

2020 ◽

Vol 21 (1) ◽

Author(s):

Nga TQ. Nguyen ◽

Alexander P. Maxwell ◽

Michael Donnelly ◽

Ciaran O’Neill

Keyword(s):

Native American ◽

Renal Disease ◽

Ethnic Groups ◽

End Stage Renal Disease ◽

Ethnic Disparities ◽

Policy Changes ◽

The Us ◽

Stage Renal Disease ◽

End Stage ◽

The Impact

Abstract Background A series of policy changes in 2011 altered reimbursement arrangements and guidance on use of erythropoiesis-stimulating agents for end-stage renal disease (ESRD) patients with anaemia in the US. While the policy changes were principally directed at care delivered in an outpatient setting, these had the potential to affect inpatient care also. This study used HCUP-NIS data (2008–2016) to examine trends in recorded anaemia among ESRD hospitalizations and analyse disparities in inpatient outcomes among ethnic groups following policy changes. Methods The International Classification of Diseases codes were used to identify ESRD admissions, recorded anaemia due to chronic kidney disease (CKD), and to generate an age-adjusted Deyo-Charlson comorbidity index. Linear splines with a knot placed at the time point of policy changes and multivariable logistic regression were used to examine the likelihood of recorded anaemia, adjusted for a range of socio-demographic and clinical covariates. Difference-in-difference analyses investigated the impact of policies on recorded anaemia. Other outcomes included hospital cost, mortality and place of discharge. Results The percentage of inpatient episodes with recorded anaemia arising from CKD increased from 26.2% in 2008 to 50.0% in 2016. Anaemia was more likely to be recorded as a complication of ESRD among minority ethnic groups and Native American admissions, in particular, (OR 1.20, 95%CI 1.15–1.25) relative to White American admissions; and these disparities widened following changes to reimbursement. Minorities were less likely to die in hospital and to be discharged to another healthcare facility, and (with the exception of Black American admissions) they were more expensive to treat. Conclusions Our findings provide evidence of an increase in recorded anaemia consistent with a shift of patients from outpatient to inpatient settings in the wake of changes to reimbursement enacted in 2011. In addition, the study highlights the existence of ethnic disparities that widened after the policy initiated reimbursement changes.

Download Full-text